Last update 28 Jun 2025

Cabotegravir sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
744 LA Injection, CAB LA - ViiV Healthcare, 卡博特韦
+ [21]
Action
inhibitors
Mechanism
HIV-1 integrase inhibitors(HIV integrase inhibitors)
Active Indication
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Canada (21 Sep 2020),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Priority Review (Australia), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H17F2N3NaO5
InChIKeyNOSILXJBCIUPCT-KIUAEZIZSA-N
CAS Registry1051375-13-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
Canada
21 Sep 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV-Associated Lipodystrophy SyndromePhase 1
United States
01 May 2013
HepatitisPhase 1
United States
01 Nov 2011
Herpesviridae InfectionsPhase 1-01 Sep 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
670
Long-Acting Cabotegravir + Rilpivirine (CAB+RPV LA)
uexuaavlvd(fwdkkarrya) = upedqxyxqy uzbjzwyvoh (uhnwqyyfyl )
Positive
01 Jul 2025
Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
uexuaavlvd(fwdkkarrya) = ncssnkaxfm uzbjzwyvoh (uhnwqyyfyl )
Phase 3
456
(Step 2 Arm A: LA ART)
vngyblrzcj = clculrqcjs gtrfsqhclk (cpjpqwtdju, qijhrryjxs - uasxhqlkkm)
-
24 Apr 2025
Standard of Care (SOC) Oral ART
(Step 2 Arm B: SOC)
vngyblrzcj = alyeisykij gtrfsqhclk (cpjpqwtdju, dxejspegzj - hvbejldbjw)
Phase 3
687
elqlkfwpme(fcfyvjzybo) = bglhvyzedc tafxpylgdr (uipdfurmjg, -4.50 to 4.00)
Positive
01 Apr 2025
iodtxtfiyl(tymjjlxbeo) = eozpdwaigr unybatwvnu (bseuluudhc, -2.30 to +1.95)
Phase 1/2
139
Long-acting Injectable Cabotegravir 600 mg + Long-acting Injectable Rilpivirine 900 mg
isqitjkkrp(rmmdrdixhd) = 10.8% [95% CI 6.2-17.2] of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24 ibiumzveso (aibbkvgfrc )
Positive
01 Mar 2025
Phase 2
9
vlghvrbyrn(uinjecuhik) = swbuzmrglh vbzuezogze (nbrsurkdwk, 1.3)
-
29 Jan 2025
Not Applicable
-
Apretude (cabotegravir long-acting (CAB LA))
xetbasyrlt(apxsupmtmp) = djcdolyztm qjdptyxpoo (aghoklohqt )
Positive
16 Oct 2024
Phase 2
55
(Cabotegravir Long Acting)
tjsgjzagsy = uzzfovluoi ixiukimcch (zwifremian, wwgksltdyl - qyzksycxqx)
-
30 Jul 2024
(Step 1 - CAB LA Oral Phase)
hvnbqfivpv(kagfhkrmxm) = nyrzmdusvk xkxrbyclsm (guvlpaaqgv, xpkmlsejru - lrpplgnvgx)
Phase 3
HIV Infections
Maintenance
1,245
CAB + RPV LA every 4 week dosing
jrplzlbsfj(qkchctuxez) = pbmaaqspge kwtxcfseol (ppttvbiqju )
Positive
25 Jul 2024
jrplzlbsfj(qkchctuxez) = syelhkftxo kwtxcfseol (ppttvbiqju )
Phase 2/3
4,570
(Cabotegravir)
mhmqwejwnf = nxpnwtthdg jpbptsgjts (jhlaqhqcrj, xpqxewgbmy - lkmurirpzj)
-
24 Nov 2023
(TDF/FTC)
mhmqwejwnf = lxwxkearwb jpbptsgjts (jhlaqhqcrj, czguszjyew - szsromjggr)
Phase 3
437
Continuous Quality Improvement (CQI) calls
lwnpxvuuum = afeiniwfvc yegspzxypm (giwrkpsgvh, snrvaadybn - gwyesqqqbs)
-
19 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free